Arguments about out timeframes to bring the device to market and the competition, have nothing to do with the patients and their chances for survival. You might find this amazing, neither does the share price during these initial Australian trials.
The stock is overpriced and most can see that.
Great vlaue at $1.90
Good luck to all patients now and in the future.